Notably, inhibitors of the renin–angiotensin–aldosterone system, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), which are widely prescribed in the management of CKD, seems also to reduce the production of pro-inflammatory products by, at least in part, inhibiting the NF-kB pathway (24). Here, NFKB1 is linked to chronic kidney disease.